Abirtega — Medica
Prostate cancer – very-high-risk group
Initial criteria
- age ≥ 18 years
- used in combination with prednisone
- patient is in the very-high-risk group (e.g., primary Gleason pattern 5; ≥ 2–3 high-risk features; > 4 cores with Grade Group 4 or 5; tumor invades seminal vesicles or adjacent structures)
- used in combination with external beam radiation therapy
- ONE of the following: concurrently used with a gonadotropin-releasing hormone (GnRH) analog OR patient has had a bilateral orchiectomy
Approval duration
2 years